Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/mTOR pathway via targeting JAK-STAT signaling of CD4+ cells

• Main Authors: Shuang Chen (Author), Caihua Li (Author), Zeng Tu (Author), Tao Cai (Author), Xinying Zhang (Author), Lei Wang (Author), Ruoyuan Tian (Author), Jinglan Huang (Author), Yuxuan Gong (Author), Xiaotong Yang (Author), Zetong Wu (Author), Sirong He (Author), Wenyan He (Author), Dan Wang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

As an inflammatory disease with a disrupted immune system, cytokine disorders in atopic dermatitis (AD) are closely related to the abnormal activation of JAK-STAT signal pathway. The critical relevance of the JAK-STAT signaling pathway to the pathogenesis of AD provides a strong rationale for JAK in...